Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 9, 2008 - Issue 12
Submit an article Journal homepage
266
Views
24
CrossRef citations to date
0
Altmetric
Review

Treatment strategies for amyloid A amyloidosis

T Pettersson Senior Lecturer, University of Helsinki and University Central Hospital, Department of Medicine, Helsinki, Finland
, MD PhD,
YT Konttinen Professor of Medicine, University of Helsinki and University Central Hospital, Department of Medicine, Helsinki, and ORTON Orthopaedic Hospital of the Invalid Foundation, Helsinki, and COXA Hospital for Joint Replacement, Tampere, Finland
, MD PhD &
CPJ Maury Professor of Medicine, University of Helsinki Department of Medicine, Kasarmikatu 11-13, FI-00130 Helsinki, Finland +358 9 47188686; +358 9 47188688; [email protected]
, MD PhD
Pages 2117-2128 | Published online: 31 Jul 2008

Bibliography

  • Pepys MB. Amyloidosis. Ann Rev Med 2006;57:223-41
  • Husby G, Marhaug G, Dowton B, et al. Serum amyloid A (SAA): biochemistry, genetics and the pathogenesis of AA amyloidosis. Amyloid 1994;1:119-37
  • Merlini G, Westermark P. The systemic amyloidoses: clearer understanding of the molecular mechanisms offers hope for more effective therapies. J Int Med 2004;255:159-78
  • Ajiro J, Narita I, Sato F, et al. SAA1 gene polymorphisms and the risk of AA amyloidosis in Japanese patients with rheumatoid arthritis. Mod Rheumatol 2006;16:294-9
  • Maury CPJ, Aittoniemi J, Tiitinen S, et al. Variant mannose-binding lectin 2 genotype is a risk factor for reactive systemic amyloidosis in rheumatoid arthritis. J Int Med 2007;262:466-9
  • Hasegawa H, Nishi SI, Ito S, et al. High prevalence of serum apolipoprotein E4 isoprotein in rheumatoid arthritis patients with amyloidosis. Arthritis Rheum 1996;39:1728-32
  • Maury CPJ, Liljeström M, Tiitinen S, et al. Apolipoprotein E phenotypes in rheumatoid arthritis with or without amyloidosis. Amyloid 2001;8:270-3
  • deBeer FC, Mallya RK, Fagan EA, et al. Serum amyloid A protein (SAA) concentration in inflammatory disease and its relationship to the incidence of reactive systemic amyloidosis. Lancet 1982;2:231-4
  • Myllykangas-Luosujärvi R, Aho K, Kautiainen H, et al. Amyloidosis in a nationwide series of 1666 subjects with rheumatoid arthritis who died during 1989 in Finland. Rheumatology 1999;38:499-503
  • Laiho K, Tiitinen S, Kaarela K, et al. Secondary amyloidosis has decreased in patients with inflammatory joint disease in Finland. Clin Rheumatol 1999;18:122-3
  • Hazenberg BPC, Van Rijswijk MH. Where has secondary amyloidosis gone? Ann Rheum Dis 2000;59:577-9
  • Tunca M, Akar S, Onen F, et al. Familial Mediterranean fever (FMF) in Turkey: results of a nationwide multicenter study. Medicine 2005;84:1-11
  • Touitou I, Sarkisian T, Medlej-Hashim M, et al. Country as the primary risk factor for amyloidosis in familial Mediterranean fever. Arthritis Rheum 2007;56:1706-12
  • Greenstein AJ, Sachar DB, Panday AK, et al. Amyloidosis and inflammatory bowel disease. A 50 year experience with 25 patients. Medicine 1992;71:261-70
  • Lähdevirta J, Maury CPJ, Teppo AM, et al. Elevated levels of circulating cachectin/tumor necrosis factor in patients with acquired immunodeficiency syndrome. Am J Med 1988;85:289-91
  • Maury CPJ, Juvonen ER, Lähdevirta J, et al. Mechanism of anaemia and cachexia of chronic disease: evidence for a role of interleukin 1β and tumour necrosis factor-α. Eur J Int Med 1991;2:159-64
  • Roubenoff R. Physical activity, inflammation, and muscle loss. Nutr Rev 2007;65:S208-12
  • Maury CPJ, Andersson LC, Teppo AM, et al. Mechanism of anaemia in rheumatoid arthritis: demonstration of raised interleukin 1β concentrations in anemic patients and of interleukin 1 mediated suppression of normal erythropoiesis and proliferation of human erythroleukemia (HEL) cells in vitro. Ann Rheum Dis 1988;47:972-8
  • Maury CPJ, Liljeström M, Laiho K, et al. Tumor necrosis factor-α, its soluble receptor 1 and –308 gene promoter polymorphism in patients with rheumatoid arthritis with or without amyloidosis. Indications for the pathogenesis of nephropathy and anemia of chronic disease in reactive amyloidosis. Arthritis Rheum 2003;48:3068-76
  • Maury CPJ, Liljeström M, Laiho K, et al. Anaemia of chronic disease in AA amyloidosis is associated with allele 2 of the interleukin-1β-511 promoter gene and raised levels of interleukin-1β and interleukin-18. J Int Med 2004;256:145-52
  • Maury CPJ, Tiitinen S, Laiho K, et al. Raised circulating interleukin-18 levels in reactive AA-amyloidosis. Amyloid 2002;9:141-4
  • Migita K, Yamasaki S, Shibatomi K, et al. Impaired degradation of serum amyloid A (SAA) protein by cytokine-stimulated monocytes. Clin Exp Immunol 2001;123:408-11
  • Falck HM, Maury CPJ, Teppo AM, et al. Correlation of persistently high serum amyloid A protein and C-reactive protein concentrations with rapid progression of secondary amyloidosis. BMJ 1983;286:1391-3
  • Lachmann HJ, Goodman HJB, Gilbertson JA, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med 2007;356:2361-71
  • Brennan FM, Chantry D, Jackson A, et al. Inhibitory effects of TNFα antibodies on synovial cell interleukin-I production in rheumatoid arthritis. Lancet 1989;ii:244-7
  • Souza DG, Guabiraba R, Pinho V, et al. IL-1-driven endogenous IL-10 production protects against the systemic and local acute inflammatory response following intestinal reperfusion injury. J Immunol 2003;170:4759-66
  • Netea MG, Kullberg BJ, Boerman OC, et al. Soluble murine IL-1 receptor type I induces release of constitutive IL-1α. J Immunol 1999;162:4876-81
  • Oldenburg HS, Rogy MA, Lazarus DD, et al. Cachexia and the acute-phase protein response in inflammation are regulated by interleukin-6. Eur J Immunol 1993;23:1889-94
  • Malfait AM, Verbruggen G, Veys EM, et al. Comparative and combined effects of interleukin 6, interleukin 1 beta, and tumor necrosis factor alpha on proteoglycan metabolism of human articular chondrocytes cultured in agarose. J Rheumatol 1994;21:314-20
  • Matsuno H, Yudoh K, Katayama R, et al. The role of TNF-alpha in the pathogenesis of inflammation and joint destruction in rheumatoid arthritis (RA): a study using a human RA/SCID mouse chimera. Rheumatology (Oxford) 2002;41:329-37
  • Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 2002;10:417-26
  • Agostini L, Martinon F, Burns K, et al. NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 2004;20:319-25
  • Keller M, Rüegg A, Werner S, et al. Active caspase-1 is a regulator of unconventional protein secretion. Cell 2008;132:818-31
  • Mihara M, Shiina M, Nishimoto N, et al. Anti-interleukin 6 receptor antibody inhibits murine AA-amyloidosis. J Rheumatol 2004;31:1132-8
  • Dinarello CA. IL-18: a TH1-inducing, proinflammatory cytokine and new member of the IL-1 family. Allergy Clin Immunol 1999;103:11-24
  • Tanaka F, Migita K, Kawabe Y, et al. Interleukin-18 induces serum amyloid A (SAA) protein production from rheumatoid synovial fibroblasts. Life Sci 2004;74:1671-9
  • Gracie JA, Forsey RJ, Ling Chan W, et al. A proinflammatory role for IL-18 in rheumatoid arthritis. J Clin Invest 1999;104:1393-401
  • Shapiro DL, Spiera H. Regression of the nephrotic syndrome in rheumatoid arthritis and amyloidosis treated with azathioprine: a case report. Arthritis Rheum 1995;38:1851-4
  • Komatsuda A, Morita K, Ohtani H, et al. Remission of the nephrotic syndrome in a patient with renal amyloidosis due to rheumatoid arthritis treated with prednisolone and methotrexate. Am J Kidney Dis 1998;32:E7
  • Ahlmen M, Ahlmen J, Svalander C, Bucht H. Cytotoxic drug treatment of reactive amyloidosis in rheumatoid arthritis with special reference to renal insufficiency. Clin Rheumatol 1987;6:27-38
  • Berglund K, Keller C, Thysell H. Alkylating cytostatic treatment in renal amyloidosis secondary to rheumatoid disease. Ann Rheum Dis 1987;46:757-62
  • Savolainen HA. Chlorambucil in severe juvenile chronic arthritis: longterm follow-up with special reference to amyloidosis. J Rheumatol 1999;26:898-903
  • Elkayam O, Hawkins PN, Lachmann H, et al. Rapid and complete resolution of proteinuria due to renal amyloidosis in a patient with rheumatoid arthritis treated with infliximab. Arthritis Rheum 2002;46:2571-3
  • Gottenberg JE, Merle-Vincent F, Bentaberry F, et al. Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a follow-up report of tolerability and efficacy. Arthritis Rheum 2003;48:2019-24
  • Nakamura T, Higashi S, Tomoda K, et al. Efficacy of etanercept in patients with AA amyloidosis secondary to rheumatoid arthritis. Clin Exp Rheumatol 2007;25:518-22
  • Perry ME, Stirling A, Hunter JA. Effect of etanercept on serum amyloid A protein (SAA) levels in patients with AA amyloidosis complicating inflammatory arthritis. Clin Rheumatol 2008; [Epub ahead of print]
  • Maini RN, Taylor OPC, Szechinski J, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had incomplete response to methotrexate. Arthritis Rheum 2006;54:2817-29
  • Okuda Y, Takasugi K. Successful use of humanized anti-interleukin-6 receptor antobody, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis. Arthritis Rheum 2006;54:2997-3000
  • Gillmore JD, Lovat LB, Persey MR, et al. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet 2001;358:24-9
  • Yan SD, Zhu H, Zhu A, et al. Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis. Nat Med 2000;6:643-51
  • Ganapathi MK, May LT, Scultz D, et al. Role of interleukin-6 in regulating synthesis of C-reactive protein and serum amyloid A in human hepatoma cell lines. Biochem Biophys Res Commun 1988;157:271-7
  • Grehan S, Uhlar CM, Sim RB, et al. Expression of biologically active recombinant mouse IL-1 receptor antagonist and its use in vivo to modulate aspects of the acute phase response. J Immunol 1997;159:369-78
  • Rokita H, Loose LD, Bartle LP, Sipe JD. Synergism of interleukin 1 and interleukin 6 induces serum amyloid A production while depressing fibrinogen: a quantitative analysis. J Rheumatol 1994;21:400-5
  • Leslie KS, Lachmann HJ, Bruning E, et al. Phenotype, genotype, and sustained response to anakinra in 22 patients with autoinflammatory disease associated with CIAS-1/NALP3 mutations. Arch Dermatol 2006;142:1591-7
  • Thornton BD, Hoffman HM, Bhat A, Don BR. Successful treatment of renal amyloidosis due to familial cold autoinflammatory syndrome using an interleukin 1 receptor antagonist. Am J Kidney Dis 2007;49:477-81
  • Stojanov S, Kastner DL. Familial autoinflammatory diseases: genetics, pathogenesis and treatment. Curr Opin Rheumatol 2005;17:586-99
  • Brydges S, Kastner DL. The systemic autoinflammatory diseases: inborn errors of the innate immune system. CTMI 2006;305:127-60
  • Padeh S, Berkun Y. Auto-inflammatory fever syndromes. Rheum Dis Clin North Am 2007;33:585-623
  • Stankovic K, Grateau G. Autoinflammatory syndromes: diagnosis and treatment. J Bone Spine 2007;74:544-50
  • Grateau G. Musculoskeletal disorders in secondary amyloidosis and hereditary fevers. Best Pract Res Clin Rheumatol 2003;17:929-44
  • Grateau G, Jeru I, Rouaghe S, et al. Amyloidosis and autoinflammatory syndromes. Curr Drug Targets Inflamm Allergy 2005;4:57-65
  • Van der Hilst JCH, Simon A, Drenth JPH. Hereditary periodic fever and reactive amyloidosis. Clin Exp Med 2005;5:87-98
  • Zemer D, Pras M, Sohar E, et al. Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. N Engl J Med 1986;314:1001-5
  • Calguneri M, Apras S, Ozbalkan Z, et al. The efficacy of continuous interferon alfa administration as an adjunctive agent to colchicine resistant familial Mediterranean fever patients. Clin Exp Rheumatol 2004;22:S41-4
  • Belkhir R, Moulonguet-Doleris L, Haculla E, et al. Treatment of familial Mediterranean fever with anakinra. Ann Intern Med 2007;146:825-6
  • Hull KM, Drewe E, Aksentijevich I, et al. The TNF receptor-associated periodic syndrome (TRAPS): emerging concepts of an autoinflammatory disorder. Medicine (Baltimore) 2002;81:349-68
  • Drewe E, McDermott EM, Powell PT, et al. Prospective study of anti-tumour necrosis factor receptor superfamily 1B fusion protein, and a case study of anti-tumour necrosis factor receptor superfamily 1A fusion protein, in tumour necrosis factor receptor-associated periodic syndrome (TRAPS): clinical and laboratory findings in a series of seven patients. Rheumatology (Oxford) 2003;42:235-9
  • Drewe E, McDermott EM, Powell RJ. Treatment of the nephrotic syndrome with etanercept in patients with the tumor necrosis factor receptor-associated periodic syndrome. N Engl J Med 2000;343:1044-5
  • Simon A, Bodar EJ, van der Hilst JC, et al. Beneficial response to interleukin 1 receptor antagonist in TRAPS. Am J Med 2004;117:208-10
  • Hawkins PN, Lachmann HJ, Aganna E, et al. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum 2004;50:607-12
  • Hoffman HM, Rosengren S, Boyle DL, et al. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 2004;364:1779-85
  • Thornton BD, Hoffman HM, Bhat A, Don BR. Successful treatment of renal amyloidosis due to familial cold autoinflammatory syndrome using an interleukin 1 receptor antagonist. Am J Kidney Dis 2007;49:477-81
  • Aganna E, Hawkins PN, Ozen S, et al. Allelic variants in genes associated with hereditary periodic fever syndrome as susceptibility factors for reactive systemic AA amyloidosis. Genes Immun 2004;5:289-93
  • Goldbach-Mansky R, Dailey NJ, Canna SW, et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1β inhibition. N Engl J Med 2006;355:581-92
  • Obici L, Manno C, Muda AO, et al. First report of systemic reactive (AA) amyloidosis in a patient with the hyperimmunoglobulinemia D with periodic fever syndrome. Arthritis Rheum 2004;50:2966-9
  • Lachmann HJ, Goodman HJB, Andrews PA, et al. AA amyloidosis complicating hyperimmunoglobulinemia D with periodic fever syndrome. Arthritis Rheum 2006;54:2010-4
  • Siewert R, Ferber J, Horstmann RD, et al. Hereditary periodic fever with systemic amyloidosis: is hyper-IgD syndrome really a benign disease. Am J Kidney Dis 2006;48:E41-5
  • Takada K, Aksentijevich I, Mahadevan V, et al. Favorable preliminary experience with etanercept in two patients with the hyperimmunoglobulinemia D and periodic fever syndrome. Arthritis Rheum 2003;48:2645-51
  • Cailliez M, Garaix F, Rousset-Rouviere C, et al. Anakinra is safe and effective in controlling hyperimmunoglobulinemia D syndrome-associated febrile crisis. J Inherit Metab Dis 2006;29:763
  • Simon A, Drewe E, van der Meer JW, et al. Simvastatin treatment for inflammatory attacks of the hyperimmunoglobulinemia D and periodic fever syndrome. Clin Pharmacol Ther 2004;75:476-83
  • Van der Hilst JCH, Kluve-Beckerman B, Bodar EJ, et al. Lovastatin inhibits formation of AA amyloid. J Leukocyt Biol 2008;83:1295-9
  • Mullin GE, Lazenby AJ, Harris ML, et al. Increased interleukin-2 messenger RNA in the intestinal mucosal lesions of Crohn's disease but not ulcerative colitis. Gastroenetrology 1992;102:1620-7
  • Fuss IJ, Neurath M, Boivirant M, et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease: Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol 1996;157:261-70
  • Murch SH, Lamkin VA, Savage MO, et al. Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut 1991;32:913-7
  • Gonvers JJ, Julierat P, Mottet C, et al. Maintenance of medically induced remission of Crohn's disease. Digestion 2007;76:116-29
  • Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007;369:1641-5
  • Iizuka M, Konno S, Horie Y, et al. Infliximab as a treatment for systemic amyloidosis associated with Crohn's disease. Gut 2006;55:744-5
  • Bosca MM, Perez-Baylach CM, Solis MA, et al. Secondary amyloidosis in Crohn's disease. Treatment with tumour necrosis factor inhibitor. Gut 2006;55:284-5
  • Fernandez-Nebro A,Urena I, Irigoyen MV, et al. Anti-TNF-α for treatment of amyloidosis associated with Crohn's disease. Gut 2006;55:1666-7
  • Amemori S, Iwakiri R, Endo H, et al. Oral dimethyl sulfoxide for systemic AA amyloidosis complication in chronic inflammatory disease: a retrospective patient chart review. J Gastroenterol 2006;41:444-9
  • Iwakiri R, Sakemi T, Fujimoto K. Dimethylsulfoxide for renal dysfunction caused by systemic amyloidosis complicating Crohn's disease. Gastroenterology 1999;117:1031-2
  • Hazenberg BPC, van Rijswijk MH. Clinical and therapeutic aspects of AA amyloidosis. Baillieres Clin Rheumatol 1994;8:661-90
  • Knutar O, Pettersson T, Törnroth T, Maury CPJ. AA amyloidosis without definable underlying disease. In: Bely M, Apathy A, editors, Amyloid and amyloidosis. Proceedings of the IX International Symposium on Amyloidosis. Budapest, Hungary; 2001. p. 168-70
  • Bergesio F, Ciciani AM, Manganaro M. Renal involvement in systemic amyloidosis. Nephrol Dial Transplant 2008;23:941-51
  • Immonen K, Finne P, Hakala M, et al. No improvement in survival of patients with amyloidosis associated with inflammatory rheumatic diseases. Data from the Finnish national registry for kidney diseases. J Rheumatol 2008; [Epub ahead of print]
  • Heering P, Hetzel R, Grabensee B, et al. Renal transplantation in secondary systemic amyloidosis. Clin Transplant 1998;12:159-64
  • Keven K, Sengui S, Kutlay S, et al. Long-term outcome of renal transplantation in patients with familial Mediterranean fever amyloidosis: a single-center experience. Transplant Proc 2004;36:2632-4
  • Pepys MB, Herbert J, Hutchinson W, et al. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 2002;417:254-9
  • Dember LM, Hawkins PN, Hazenberg BPC, et al. Eprodisate for the treatment of renal disease in AA amyloidosis. N Engl J Med 2007;356:2349-60
  • McInnes IB, Liew FY. Cytokine networks – towards new therapies for rheumatoid arthritis. Nat Clin Pract Rheumatol 2005;1:31-9
  • Rochet JC. Novel therapeutic strategies for the treatment of protein-misfolding diseases. Expert Rev Mol Med 2007;28:1-34
  • Sacchettini JC, Kelly JW. Therapeutic strategies for human amyloid diseases. Nat Rev Drug Res 2002;1:267-75
  • O´Nuallain B, Wetzel R. Conformational Abs recognizing a generic amyloid fibril epitope. Proc Natl Acad Sci USA 2002;99:1485-90
  • McGavern DB. Immunotherapeutic relief from persistent infections and amyloid disorders. Neurology 2006;66(Suppl 1):S59-64
  • Wisniewski T, Frangione B. Immunological and anti-chaperone therapeutic approaches for Alzheimer disease. Brain Pathol 2005;15:72-7
  • Li J-P, Galvis MLE, Gong F, et al. In vivo fragmentation of heparan sulfate by heparanase overexpression renders mice resistant to amyloid protein A amyloidosis. Proc Natl Acad Sci USA 2005;102:6473-7
  • Lidar M, Livneh A. Familial Mediterranean fever: clinical, molecular and management advancements. Neth J Med 2007;65:318-24
  • Kobak S, Oksel F, Kabasakai Y, et al. Ankylosing spondylitis-related secondary amyloidosis responded to etanercept: a report of three patients. Clin Rheumatol 2007;26:21291-4
  • Nishimoto N, Sasai M, Shima Y, et al. Improvement of Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 2000;85:56-61

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.